Biotech Values

[projectchris]

I think you are missing the fact that it looks like they only tested CTx in patients with cancers where bone mets are reasonably common. Thus in the non-prostate cohort where they tested Ctx, over 60% (46/73) in fact had bone mets. So it's not too surprising that the effect was similar.



Interestingly ovarian cohort had a total of 70 patients, and described 6(9%) of which had bone metastasis. That is an unusually high number of patients compared to historical numbers I've seen. Mostly under 1% of Ovarian cancer population.

I want to look at Lung cohert as well, but I'm wondering why we don't see before and after bone scans in these tumor types? I'm guessing this population didn't get a baseline bone scan. Lung Cancer is typical to see bone mets, and prognosis is horrible an average of 6 month survival with bone mets. I'm surprised Exelixis hasn't followed up on this cohort more to get some bone scan data.